Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ASND NASDAQ:GMAB NASDAQ:PTCT NYSE:RDY On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeASNDAscendis Pharma A/S$183.41-0.4%$171.88$111.09▼$185.00$11.22B0.41482,268 shs321,414 shsGMABGenmab A/S$22.13+0.7%$21.68$17.24▼$27.94$14.19B0.951.44 million shs485,425 shsPTCTPTC Therapeutics$51.00-2.4%$49.21$29.01▼$58.38$4.04B0.541.05 million shs464,711 shsRDYDr. Reddy's Laboratories$13.75-0.3%$14.94$12.26▼$16.89$11.49B0.291.91 million shs534,267 shs5G Stocks: The Path Forward is ProfitableEnter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceASNDAscendis Pharma A/S+5.54%+12.18%+5.79%+13.34%+39.23%GMABGenmab A/S+0.92%-4.81%+7.69%+7.64%-22.17%PTCTPTC Therapeutics+0.23%+17.80%+7.13%+44.38%+62.32%RDYDr. Reddy's Laboratories-1.11%-6.19%-8.52%+2.07%-17.10%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationASNDAscendis Pharma A/S2.476 of 5 stars3.52.00.00.02.61.70.6GMABGenmab A/S3.5362 of 5 stars3.33.00.00.03.20.03.1PTCTPTC Therapeutics4.5005 of 5 stars4.32.00.04.43.00.81.3RDYDr. Reddy's Laboratories2.1224 of 5 stars2.52.01.70.01.90.01.9Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceASNDAscendis Pharma A/S 3.00Buy$223.6721.95% UpsideGMABGenmab A/S 2.64Moderate Buy$37.8070.85% UpsidePTCTPTC Therapeutics 2.67Moderate Buy$69.3836.05% UpsideRDYDr. Reddy's Laboratories 3.00Buy$16.9523.25% UpsideCurrent Analyst Ratings BreakdownLatest PTCT, GMAB, RDY, and ASND Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails7/29/2025ASNDAscendis Pharma A/SJPMorgan Chase & Co.Subscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOverweight ➝ Overweight$245.00 ➝ $254.007/29/2025PTCTPTC TherapeuticsTruist FinancialSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$80.00 ➝ $86.007/29/2025PTCTPTC TherapeuticsBarclaysSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetEqual Weight ➝ Equal Weight$42.00 ➝ $46.007/29/2025PTCTPTC TherapeuticsBank of AmericaSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$68.00 ➝ $84.007/29/2025PTCTPTC TherapeuticsUBS GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$71.00 ➝ $80.007/29/2025PTCTPTC TherapeuticsCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOverweight ➝ Overweight$112.00 ➝ $120.007/29/2025PTCTPTC TherapeuticsWells Fargo & CompanySubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOverweight ➝ Overweight$74.00 ➝ $78.007/28/2025PTCTPTC TherapeuticsCitigroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingNeutral ➝ Neutral$40.00 ➝ $50.007/11/2025ASNDAscendis Pharma A/SCitigroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$213.00 ➝ $243.007/8/2025GMABGenmab A/STruist FinancialSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$45.00 ➝ $46.007/3/2025ASNDAscendis Pharma A/SMorgan StanleySubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOverweight$250.00(Data available from 8/5/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookASNDAscendis Pharma A/S$393.54M28.50N/AN/A($1.88) per share-97.56GMABGenmab A/S$3.12B4.55$1.54 per share14.36$8.04 per share2.75PTCTPTC Therapeutics$806.78M5.01N/AN/A($14.24) per share-3.58RDYDr. Reddy's Laboratories$334.26B0.03$1.02 per share13.50$4.73 per share2.91Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateASNDAscendis Pharma A/S-$409.12M-$6.28N/A764.19N/A-93.22%N/A-33.29%8/7/2025 (Estimated)GMABGenmab A/S$1.14B$1.7612.5712.436.6235.11%18.08%14.52%8/7/2025 (Estimated)PTCTPTC Therapeutics-$363.30M$6.517.83N/AN/A33.56%-78.56%32.11%8/7/2025 (Estimated)RDYDr. Reddy's Laboratories$663M$0.6620.8516.775.5716.99%17.25%11.63%N/ALatest PTCT, GMAB, RDY, and ASND EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/7/2025Q2 2025ASNDAscendis Pharma A/S-$1.42N/AN/AN/A$163.17 millionN/A8/7/2025Q2 2025GMABGenmab A/S$0.39N/AN/AN/A$5.77 billionN/A8/7/2025Q2 2025PTCTPTC Therapeutics-$1.07N/AN/AN/A$173.01 millionN/A7/23/2025Q1 25/26RDYDr. Reddy's Laboratories$0.18$0.20+$0.02$0.20$88.27 billion$988.82 million5/9/2025Q4 24/25RDYDr. Reddy's Laboratories$0.20$0.22+$0.02$0.22$83.70 billion$996.17 million5/8/2025Q1 2025GMABGenmab A/S$0.23$0.31+$0.08$0.31$5.17 billion$715.00 million5/6/2025Q1 2025PTCTPTC Therapeutics$0.85$10.04+$9.19N/A$437.16 million$1.18 billionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthASNDAscendis Pharma A/SN/AN/AN/AN/AN/AGMABGenmab A/SN/AN/AN/AN/AN/APTCTPTC TherapeuticsN/AN/AN/AN/AN/ARDYDr. Reddy's Laboratories$0.070.51%N/A10.61%N/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioASNDAscendis Pharma A/SN/A1.040.71GMABGenmab A/SN/A5.345.32PTCTPTC TherapeuticsN/A3.893.85RDYDr. Reddy's Laboratories0.011.891.36Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipASNDAscendis Pharma A/SN/AGMABGenmab A/S7.07%PTCTPTC TherapeuticsN/ARDYDr. Reddy's Laboratories3.85%Insider OwnershipCompanyInsider OwnershipASNDAscendis Pharma A/S40.00%GMABGenmab A/S1.54%PTCTPTC Therapeutics5.50%RDYDr. Reddy's Laboratories2.00%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableASNDAscendis Pharma A/S1,01761.15 million36.69 millionOptionableGMABGenmab A/S2,682641.54 million631.66 millionOptionablePTCTPTC Therapeutics1,41079.26 million74.90 millionOptionableRDYDr. Reddy's Laboratories27,811834.90 million818.20 millionOptionablePTCT, GMAB, RDY, and ASND HeadlinesRecent News About These CompaniesDr. Reddy's: Needs To Invest $0.95 To Produce $1 Of New RevenuesAugust 4 at 6:10 AM | seekingalpha.comComparing Dr. Reddy's Laboratories (NYSE:RDY) and Acura Pharmaceuticals (OTCMKTS:ACUR)August 2 at 2:23 AM | americanbankingnews.comDr. Reddy's Laboratories Ltd (NYSE:RDY) Shares Sold by Allianz Asset Management GmbHJuly 29, 2025 | marketbeat.comHead to Head Survey: Dr. Reddy's Laboratories (NYSE:RDY) vs. Parnell Pharmaceuticals (OTCMKTS:PARNF)July 29, 2025 | americanbankingnews.comDr. Reddy’s Laboratories Releases Q1 2025 Earnings Call AudioJuly 25, 2025 | theglobeandmail.comDr. Reddy's Q1 Earnings Beat Estimates, Generics Sales Boost RevenuesJuly 24, 2025 | zacks.comDr. Reddy's Laboratories Limited (RDY) Q1 2026 Earnings Call TranscriptJuly 23, 2025 | seekingalpha.comDr. Reddy's Laboratories Limited 2026 Q1 - Results - Earnings Call PresentationJuly 23, 2025 | seekingalpha.comDr. Reddy's Q1FY26 Financial ResultsJuly 23, 2025 | businesswire.comDr. Reddy’s to launch generic semaglutide in 87 countries: BloombergJuly 23, 2025 | msn.comDr. Reddy’s Laboratories (RDY) and Alvotech Enter Into a Collaboration and License AgreementJuly 23, 2025 | msn.comCerity Partners LLC Buys 88,628 Shares of Dr. Reddy's Laboratories Ltd (NYSE:RDY)July 20, 2025 | marketbeat.comCenterBook Partners LP Makes New Investment in Dr. Reddy's Laboratories Ltd (NYSE:RDY)July 19, 2025 | marketbeat.comDr. Reddy's Laboratories Ltd (NYSE:RDY) Shares Sold by Migdal Insurance & Financial Holdings Ltd.July 19, 2025 | marketbeat.comNew Strong Sell Stocks for July 18thJuly 18, 2025 | zacks.comDr. Reddy's Laboratories (RDY) Expected to Announce Earnings on FridayJuly 18, 2025 | marketbeat.comDr. Reddy's Laboratories climbs Thursday, underperforms competitorsJuly 17, 2025 | marketwatch.comDr. Reddy’s Laboratories Ltd. (DRREDDY) Has a New Rating from Morgan StanleyJuly 16, 2025 | theglobeandmail.comSignaturefd LLC Cuts Stock Holdings in Dr. Reddy's Laboratories Ltd (NYSE:RDY)July 16, 2025 | marketbeat.comBallentine Partners LLC Lowers Stock Position in Dr. Reddy's Laboratories Ltd (NYSE:RDY)July 14, 2025 | marketbeat.comAllspring Global Investments Holdings LLC Sells 439,622 Shares of Dr. Reddy's Laboratories Ltd (NYSE:RDY)July 9, 2025 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimePTCT, GMAB, RDY, and ASND Company DescriptionsAscendis Pharma A/S NASDAQ:ASND$183.40 -0.75 (-0.40%) As of 02:35 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates. The company was incorporated in 2006 and is headquartered in Hellerup, Denmark.Genmab A/S NASDAQ:GMAB$22.12 +0.15 (+0.66%) As of 02:36 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC. Its products include daratumumab to treat MM, non-MM blood cancers, and AL amyloidosis; GEN1047; tisotumab vedotin for treating cervical, ovarian, and solid cancers; DuoBody-PD-L1x4-1BB, and DuoBody-CD40x4-1BB for treating solid tumors; Epcoritamab for relapsed/refractory diffuse large B-cell lymphoma and chronic lymphocytic leukemia; and HexaBody-CD38 and GEN3017 for treating hematological malignancies. In addition, the company develops Inclacumab, which is in Phase 3 trial for vaso-occlusive crises; Camidanlumab tesirine to treat hodgkin lymphoma and solid tumors; JNJ-64007957 and JNJ-64407564 to treat MM; PRV-015 for treating celiac disease; Mim8 for treating haemophilia A; and Lu AF82422 for treating multiple system atrophy disease. It operates various active pre-clinical programs. The company has a commercial license and collaboration agreement with Seagen Inc. to co-develop tisotumab vedotin. It also has a collaboration agreement with argenx to discover, develop, and commercialize novel therapeutic antibodies with applications in immunology and oncology; and AbbVie for the development of epcoritamab, as well as collaborations with BioNTech, Janssen, and Novo Nordisk A/S. Genmab A/S was founded in 1999 and is headquartered in Copenhagen, Denmark.PTC Therapeutics NASDAQ:PTCT$51.00 -1.25 (-2.39%) As of 02:36 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.PTC Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines to patients with rare disorders in the United States and internationally. The company offers Translarna and Emflaza for the treatment of Duchenne muscular dystrophy; Upstaza to treat aromatic l-amino acid decarboxylas (AADC) deficiency, a central nervous system disorder; Tegsedi and Waylivra for the treatment of rare diseases; and Evrysdi to treat spinal muscular atrophy (SMA) in adults and children. Its development pipeline products include Sepiapterin for the treatment of phenylketonuria; PTC518 splicing platform, which is being developed for the treatment of Huntington's disease; and ferroptosis and inflammation platforms, including vatiquinone to treat Friedreich ataxia and utreloxastat for the treatment of amyotrophic lateral sclerosis. The company distributes its products through third-party distributors. It has collaborations with F. Hoffman-La Roche Ltd, Hoffman-La Roche Inc., the SMA Foundation, National Taiwan University, Akcea Therapeutics, Inc., and Shiratori Pharmaceutical Co., Ltd. PTC Therapeutics, Inc. was incorporated in 1998 and is headquartered in South Plainfield, New Jersey.Dr. Reddy's Laboratories NYSE:RDY$13.75 -0.04 (-0.28%) As of 02:36 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Dr. Reddy's Laboratories Limited, together with its subsidiaries, operates as an integrated pharmaceutical company worldwide. It operates through Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Others segments. The company's Global Generics segment manufactures and markets prescription and over-the-counter finished pharmaceutical products that are marketed under a brand name or as a generic finished dosages with therapeutic equivalence to branded formulations, as well as engages in the biologics business. The PSAI segment manufactures and markets active pharmaceutical ingredients and intermediates, which are principal ingredients for finished pharmaceutical products. This segment also provides contract research services; and manufactures and sells active pharmaceutical ingredients and steroids in accordance with the specific customer requirements. The Others segment engages in developing therapies in the fields of oncology and inflammation; research and development of differentiated formulations; and provides digital healthcare and information technology enabled business support services. The company offers its products for various therapeutic categories primarily include gastro-intestinal, cardiovascular, anti-diabetic, dermatology, oncology, respiratory, stomatology, urology, and nephrology. Dr. Reddy's Laboratories Limited was incorporated in 1984 and is headquartered in Hyderabad, India. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Stop Overlooking Qualcomm—Here’s What the Market’s Missing Amazon Enters Correction Zone: Time to Panic or Be Brave? Figma's Wild IPO Ride: Is the Stock's Premium Price Justified? META Gets Huge Upgrades: How High Analysts Think Shares Could Go Novo Nordisk Stock Sinks—But Is a Bottom Finally In? Why Citigroup Analysts See Double-Digit Upside in Coinbase Stock A New AI Tailwind Could Come to Boost Taiwan Semiconductor Stock How 2 Deals in 48 Hours Changed Everything for Joby Aviation Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
